This trial evaluated the immunogenicity and safety profiles of a bivalent aerosolized adenovirus-vectored COVID-19 vaccine and an intramuscular bivalent mRNA booster. The mRNA booster induced higher neutralizing antibody levels and a distinct memory B cell response, yet was associated with a higher incidence of adverse reactions.
- Shipo Wu
- Jianying Huang
- Lihua Hou
